Virtualization in Pharmaceutical R&D

Please note that the Virtualization in Pharmaceutical R&D report is currently in the final stages of production, and will be emailed to registered users shortly upon its completion.

It is widely recognised that the pharmaceutical industry is facing a series of
serious challenges: declining productivity despite spiraling R&D costs; revenue
erosion from patent expirations on blockbusters and generic competition; pricing
pressures from healthcare providers and payers; and increasingly stringent regulators.
Against this backdrop of constraints on finances and resources, pharmaceutical
companies are looking to several strategies to maintain growth, drive value and improve
productivity. Fundamental to the future success of the industry is the need to
improve on the return on R&D investment. This will require a shift from the integrated
in house model of R&D to models that embraces external innovation from creative
alliances and outsourcing – the virtualization of R&D.

Contents